AR017726A1 - Uso de un antagonista del rar, o una prodroga o una sal farmaceuticamente aceptable del mismo, medicamentos que los contienen y un metodo in vitro, para inhibir la expresion del gen de mucina en una celula epitelial humana - Google Patents
Uso de un antagonista del rar, o una prodroga o una sal farmaceuticamente aceptable del mismo, medicamentos que los contienen y un metodo in vitro, para inhibir la expresion del gen de mucina en una celula epitelial humanaInfo
- Publication number
- AR017726A1 AR017726A1 ARP990100934A ARP990100934A AR017726A1 AR 017726 A1 AR017726 A1 AR 017726A1 AR P990100934 A ARP990100934 A AR P990100934A AR P990100934 A ARP990100934 A AR P990100934A AR 017726 A1 AR017726 A1 AR 017726A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- rar
- pharmaceutically acceptable
- rar antagonist
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Uso de un antagonista de RAR (receptores del ácido retinoico), o una prodroga o una sal farmacéuticamente aceptable del mismo, para la preparacion de unmedicamento para la inhibicion de la produccion de mulina (referente, el antagonista del RAR es unantagonista selectivo del RAR alfa (receptor del ácidoretinoico alfa). Más preferentemente, el antagonista del RAR es seleccionado entre los compuestos de la formula (I) en donde X es S, SO, o SO2, R1 es alquiloC7-10 o alcoxi C7-10, R2 es carboxiarilo, alcoxicarbonilarilo inferior, carboxialquenilo, alcoxicarbonilalquenilo inferior, carboxialquinilo,alcoxicarbonialquinilo inferior, carboxilarilalquenilo, alcoxicarbonilarilalquenilo inferior, carboxilarilalquinilo o alcoxicarbonilarilalquinilo inferior, R3ay R3b son independientemente hidrogeno o alquilo C1-4 y n es un entero de 1 a 3 inclusive, entre los compuestos de la formula II y la formula III: en donde Xes arilo o heteroarilo, L es C(=G)NH o NH(C=G), en donde G es oxígeno o azufre, Yes arilo o heteroarilo; B es carboxi o alcoxicarbonilo inferior; Z es alquilohalo, NO2 u OH; y U es oxígeno o azufre, y entre los compuestos de formula IV y V: en donde B es un anillo carbocíclico de 5, 6 o 7 miembros fusionado; X esNR4, O, S, o CHR4 (en donde R4 es H o alquilo); A es fenileno o piridinadilo, R1 es H o alquilo; R2 y R3 son independientemente H o alquilo o R2 y R3 formanjuntos un anillo fenilo, naftilo, tetrahidronaftilo o cicloalquilo. Medicamentos para el tratamiento de enfermedades que representan indicadores terapéuticasasociadas con hipersecrecion de mucina tales como enfermedad pulmonar obstructiva cronica o asma que contiene uno o más antagonistas del RAR y excipientesfarmacéuticamente aceptables y un método in vitropara inhibir la expresion del gen de mucina en una célula epitelial humana, poniendo en contacto la célulacon un antagonista del RAR.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7732898P | 1998-03-09 | 1998-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR017726A1 true AR017726A1 (es) | 2001-09-12 |
Family
ID=22137426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990100934A AR017726A1 (es) | 1998-03-09 | 1999-03-05 | Uso de un antagonista del rar, o una prodroga o una sal farmaceuticamente aceptable del mismo, medicamentos que los contienen y un metodo in vitro, para inhibir la expresion del gen de mucina en una celula epitelial humana |
Country Status (12)
Country | Link |
---|---|
US (1) | US6083973A (es) |
EP (1) | EP1061910A1 (es) |
JP (1) | JP2002506025A (es) |
KR (1) | KR100386349B1 (es) |
CN (1) | CN1169524C (es) |
AR (1) | AR017726A1 (es) |
AU (1) | AU735382B2 (es) |
BR (1) | BR9908623A (es) |
CA (1) | CA2321935A1 (es) |
TR (1) | TR200002587T2 (es) |
WO (1) | WO1999045915A1 (es) |
ZA (1) | ZA991852B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4225500A (en) * | 1999-04-14 | 2000-11-14 | Allergan Sales, Inc. | Methods and compositions for the treatment and prevention of lung disease |
US6436993B1 (en) * | 1999-07-13 | 2002-08-20 | The Salk Institute For Biological Studies | Use of RAR antagonists as modulators of hormone mediated processes |
JO2178B1 (en) * | 1999-10-19 | 2003-04-23 | اف . هوفمان لاروش ايه جي | Treatment of invasive diseases, using selected anti-PAR materials |
AU2001290816A1 (en) * | 2000-09-13 | 2002-03-26 | Bristol-Myers Squibb Company | Retinoic acid receptor antagonists as promoters of angiogenesis |
ATE525398T1 (de) * | 2002-05-10 | 2011-10-15 | Medimmune Inc | Epha2 monoklonale antikörper und deren anwendungsverfahren |
US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
CA2485548A1 (en) * | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
EP1617864A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING |
US20080146915A1 (en) * | 2006-10-19 | 2008-06-19 | Mcmorrow Gerald | Systems and methods for visualizing a cannula trajectory |
CN107176945B (zh) * | 2016-03-11 | 2021-06-08 | 中国科学院上海有机化学研究所 | 一种视黄酸类化合物、其制备方法、中间体及应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2093577C (en) * | 1992-05-07 | 2006-01-03 | Michael Klaus | Alkyl or alkoxy substituted s-heterocyclic retinoids |
US5807900A (en) * | 1995-03-31 | 1998-09-15 | Hoffmann-La Roche, Inc. | Method for identifying compounds having increased activity for the repair of skin photodamage |
CN1121395C (zh) * | 1995-09-21 | 2003-09-17 | 药物分子设计研究所株式会社 | 类视色素作用增强性化合物 |
FR2739557B1 (fr) * | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
-
1999
- 1999-02-24 US US09/256,949 patent/US6083973A/en not_active Expired - Fee Related
- 1999-03-01 AU AU27273/99A patent/AU735382B2/en not_active Ceased
- 1999-03-01 JP JP2000535330A patent/JP2002506025A/ja active Pending
- 1999-03-01 BR BR9908623-9A patent/BR9908623A/pt not_active Application Discontinuation
- 1999-03-01 WO PCT/EP1999/001328 patent/WO1999045915A1/en not_active Application Discontinuation
- 1999-03-01 KR KR10-2000-7009951A patent/KR100386349B1/ko not_active IP Right Cessation
- 1999-03-01 CA CA002321935A patent/CA2321935A1/en not_active Abandoned
- 1999-03-01 EP EP99907579A patent/EP1061910A1/en not_active Withdrawn
- 1999-03-01 CN CNB998038113A patent/CN1169524C/zh not_active Expired - Fee Related
- 1999-03-01 TR TR2000/02587T patent/TR200002587T2/xx unknown
- 1999-03-05 AR ARP990100934A patent/AR017726A1/es unknown
- 1999-03-08 ZA ZA9901852A patent/ZA991852B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN1292690A (zh) | 2001-04-25 |
TR200002587T2 (tr) | 2000-11-21 |
JP2002506025A (ja) | 2002-02-26 |
KR20010041720A (ko) | 2001-05-25 |
US6083973A (en) | 2000-07-04 |
WO1999045915A1 (en) | 1999-09-16 |
KR100386349B1 (ko) | 2003-06-02 |
CA2321935A1 (en) | 1999-09-16 |
CN1169524C (zh) | 2004-10-06 |
AU2727399A (en) | 1999-09-27 |
AU735382B2 (en) | 2001-07-05 |
ZA991852B (en) | 1999-09-09 |
BR9908623A (pt) | 2000-11-14 |
EP1061910A1 (en) | 2000-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2020003I1 (no) | plerixafor (1,1’-[ 1,4-fenylen-bis- (metylen)]- bis1,2,8,11-tetraazacyklotetradekan) eventuelt i form av et farmasøytisk akseptabelt salt eller metallkompleks derav | |
AR017726A1 (es) | Uso de un antagonista del rar, o una prodroga o una sal farmaceuticamente aceptable del mismo, medicamentos que los contienen y un metodo in vitro, para inhibir la expresion del gen de mucina en una celula epitelial humana | |
ATE54154T1 (de) | Retro-inverse analoga des bradykininpotentialisierenden peptids bpp-5a und verfahren zu ihrer herstellung. | |
KR930006027A (ko) | 엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-메르캅토아세틸아미드 유도체 | |
AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
HUP0300148A2 (en) | Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them | |
ES2534345T3 (es) | Bitionol como agente antiangiogénico | |
ES2456067T3 (es) | Nuevas ditiolopirrolonas y sus aplicaciones terapéuticas | |
HUP0000591A2 (hu) | Fémproteáz inhibitor hatású piperazin-, morfolin- és tiomorfolin-származékok és alkalmazásuk gyógyszerkészítmények előállítására | |
HUP0102851A2 (hu) | Parazitaellenes artemizinin-származékok (endoperoxidok), eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
ES2206412T3 (es) | Derivados de 8,8a-dihidro-indeno(1,2-d)tiazol que en posicion 2 portan un sustituyente con una estructura sulfonamida o sulfona, procedimiento para su preparacion y su uso como medicamentos. | |
DE69427708D1 (de) | Stabilisierte arzneizusammensetzung enthaltend 10-hydroxy-7-ethylcamptothecin als lakton-verbindung | |
AR051391A1 (es) | Compuesto de pirrolidina antagonista del receptor h3; composicion farmaceutica que lo comprende, su uso para preparar un medicamento para el tratamiento de enfermedades neurologicas y un procedimiento para su elaboracion. | |
MX9305379A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene. | |
AR019842A1 (es) | Derivados de nafto[2,3-b]heteroar-4-ilo, el uso de los mismos para la manufactura de un medicamento y una composicion que los comprende. | |
ES2309563T3 (es) | Compuestos de piperidina utiles como inhibidores de malonil coenzima a descarboxilasa. | |
WO2003055489A1 (en) | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
BR0314591A (pt) | Métodos de aumento de plaquetas e produção de célula tronco hematopoiética | |
HUP0301080A2 (hu) | Helyettesített 1,2,3,4-tetrahidrokinolin-2-karbonsav-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
EP0322184B1 (en) | N-(2-alkyl-3-mercapto-1,5-di-oxoalkyl)glycinamide derivatives and their use as collagenase inhibitors | |
EA200100597A2 (ru) | Новые 1,1- и 1,2-дизамещенные циклопропановые соединения, способ их получения и содержащие их фармацевтические композиции | |
AR033987A1 (es) | Compuestos calcioliticos y su uso en la fabricacion de medicamentos | |
WO2018089621A1 (en) | Tricyclic p2-ligand containing potent hiv-protease inhibitors against hiv/aids | |
AR019322A1 (es) | Derivados de sulfonilo sustituido por heterociclo-etanodionanilina sustituida por heterociclo, composicion farmaceutica que los contiene y su uso para lamanufactura de un medicamento | |
ES2262504T3 (es) | Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |